CN115433132A - Enconazole crystal form, preparation method and application - Google Patents
Enconazole crystal form, preparation method and application Download PDFInfo
- Publication number
- CN115433132A CN115433132A CN202211286225.9A CN202211286225A CN115433132A CN 115433132 A CN115433132 A CN 115433132A CN 202211286225 A CN202211286225 A CN 202211286225A CN 115433132 A CN115433132 A CN 115433132A
- Authority
- CN
- China
- Prior art keywords
- enilconazole
- crystalline form
- stirring
- powder diffraction
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- PZBPKYOVPCNPJY-UHFFFAOYSA-N 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=C)CN1C=NC=C1 PZBPKYOVPCNPJY-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000005795 Imazalil Substances 0.000 claims abstract description 54
- 229960002125 enilconazole Drugs 0.000 claims abstract description 54
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 33
- 230000005855 radiation Effects 0.000 claims abstract description 5
- 229910017488 Cu K Inorganic materials 0.000 claims abstract description 4
- 229910017541 Cu-K Inorganic materials 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 24
- 238000010438 heat treatment Methods 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 5
- 238000001757 thermogravimetry curve Methods 0.000 claims description 5
- 230000003385 bacteriostatic effect Effects 0.000 claims description 3
- 238000009776 industrial production Methods 0.000 abstract description 5
- 239000002547 new drug Substances 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 25
- 239000012535 impurity Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 239000012043 crude product Substances 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000002447 crystallographic data Methods 0.000 description 6
- 230000001502 supplementing effect Effects 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910021421 monocrystalline silicon Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an enilconazole crystal form, a preparation method and application, wherein the crystal form has characteristic peaks at 9.3045, 13.3046, 14.8313, 20.2166, 20.6254, 20.7572, 21.0752, 22.7064, 22.9297, 23.4409, 23.6543, 24.4229, 25.2438, 27.7342, 28.4334 and 28.5207 in an X-ray powder diffraction pattern expressed by Cu-K alpha radiation and 2 theta +/-0.2-degree diffraction angle. The enilconazole crystal form has high purity and stability, is suitable for development of new drugs and industrial production, and has high application value.
Description
Technical Field
The invention relates to the technical field of enilconazole preparation, in particular to an enilconazole crystal form, a preparation method and application.
Background
Enilconazole (Enilconazole), also known as imazalil (imazalil), is an imidazole fungicide developed in 1973 by the company popsonian, belgium (Janssen), and formally approved for use in the united states in 1979. Enconazole is used as a broad-spectrum antifungal drug, is mainly used for treating dermatophyte infection of cows, horses and dogs in veterinary drugs, and is sold in various countries or regions all over the world at present. The chemical name of the compound is 1- [ (2 RS) -2- (2,4-dichlorophenyl) -2- (2-propenyloxy) ethyl ] -1H-imidazole, and the structural formula is as follows:
most of the enoconazole is used as an agricultural bactericide in a liquid form, and the existing synthetic enoconazole is yellow to brown oily liquid, contains a large amount of impurities which are difficult to remove in the synthesis process, is unstable during storage, and influences the prospect of the enoconazole serving as a bactericidal medicine for livestock.
The research and optimization of the solid form are known to better improve the performance of the compound, the improvement of the purity is of great significance for veterinary drugs, and at present, no literature report on the crystal form research of enilconazole exists temporarily.
The morphology of a solid compound includes a crystal form and an amorphous form, and different crystal forms of the same compound have significant differences in solubility, melting point, density, stability and the like, thereby affecting the stability and homogeneity of the compound to different degrees. The involvement and use of the appropriate specific crystalline form in the process can improve the properties of the compound, such as better handling and stability. Therefore, comprehensive systematic crystal form and amorphous screening are carried out in the research and development of the pharmaceutical technology, and the selection of the most suitable developed solid form is one of important research contents which cannot be ignored.
Disclosure of Invention
The invention aims to provide an enilconazole crystal form and a preparation method thereof, overcomes the defects of low purity, poor stability and the like of enilconazole liquid in the prior art, and promotes the development and industrial production process of enilconazole as a medicament.
In view of the above, the technical scheme of the invention is as follows:
an enilconazole crystalline form having characteristic peaks in an X-ray powder diffraction pattern expressed as Cu-K α radiation at 2 θ ± 0.2 ° diffraction angles at 9.3045, 13.3046, 14.8313, 20.2166, 20.6254, 20.7572, 21.0752, 22.7064, 22.9297, 23.4409, 23.6543, 24.4229, 25.2438, 27.7342, 28.4334, 28.5207.
Further, the crystalline form of eniconazole has an X-ray powder diffraction pattern as shown in fig. 1.
Further, a differential scanning calorimetry analysis curve of the enilconazole crystal form shows a first endothermic peak at 50-53 ℃, and the peak value of the first endothermic peak shows 53-55 ℃.
Further, the thermogravimetric analysis curve of the crystalline form of eniconazole starts to decompose at 150 ℃ and completely decomposes at 210 ℃.
The invention also aims to provide a method for preparing the enilconazole crystal form, which comprises the steps of adding a crude enilconazole product into a solvent, heating and stirring for the first time, and filtering; and (3) heating and stirring the filtered product for the second time, cooling after dissolving, stirring and crystallizing, filtering, and drying under reduced pressure to obtain the product.
Further, the solvent is one of dichloromethane, butyl acetate, methyl tert-butyl ether, n-hexane, ethyl acetate or toluene.
Further, the volume ratio of the crude enilconazole product to the solvent is 1: (0.5-10).
Further, the crystallization process time is 2-8h.
The invention also provides application of the enilconazole crystal form in preparation of bactericidal or bacteriostatic medicines.
Still another object of the present invention is to provide a method for detecting the crystalline form of enilconazole, wherein the suspected crystal is subjected to X-ray powder diffraction detection, and the obtained X-ray powder diffraction pattern is compared with the X-ray powder diffraction pattern shown in fig. 1.
The beneficial effects of the present invention include but are not limited to:
1. the eniconazole crystal form provided by the invention has higher purity and stability, is suitable for new drug development and industrial production, and has higher application value.
2. According to the preparation method of the enilconazole crystal form, the yield of the prepared enilconazole can reach more than 90%, the purity of the enilconazole crystal can reach more than 99.9%, and the single impurity content of the enilconazole crystal form is less than 0.1% through multiple times of thermal stirring and filtering. And the preparation method has simple process route and low cost and is suitable for industrial production.
3. The enilconazole crystal form provided by the invention can be used for detecting enilconazole suspected crystals, and a conclusion can be obtained according to the comparison of characteristic peaks in X-ray powder, so that the method is convenient and rapid.
Drawings
Fig. 1 is an XRPD pattern of the crystalline form of eniconazole prepared in example 1 of the present invention.
Fig. 2 is a DSC diagram of the crystalline form of eniconazole prepared in example 1 of the present invention.
Fig. 3 is a TGA diagram of an eniconazole crystalline form prepared in example 1 of the present invention.
FIG. 4 is a H-NMR chart of an eniconazole crystal form prepared in example 1 of the present invention.
FIG. 5 is an XRPD pattern versus crystalline forms of eniconazole prepared in examples 1-6 of the present invention.
FIG. 6 is a DSC of crystalline forms of eniconazole prepared in examples 1-6 of the present invention in comparison.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In one embodiment of the invention, the crystalline form of eniconazole has characteristic peaks at 9.3045, 13.3046, 14.8313, 20.2166, 20.6254, 20.7572, 21.0752, 22.7064, 22.9297, 23.4409, 23.6543, 24.4229, 25.2438, 27.7342, 28.4334, 28.5207 in an X-ray powder diffraction pattern expressed by Cu-K alpha radiation and 2 theta +/-0.2 DEG diffraction angle, has high purity and stability, is suitable for new drug development and industrial production, and has high application value.
In a preferred embodiment, the crystalline form of eniconazole has an X-ray powder diffraction pattern as shown in figure 1.
In one embodiment, the differential scanning calorimetry curve of the crystalline form of eniconazole exhibits a first endotherm at 50-53 ℃ and the peak of the first endotherm occurs at 53-55 ℃; preferably, the sample has a differential scanning calorimetry curve and a characteristic peak as shown in FIG. 2.
In one embodiment, the thermogravimetric analysis curve of the crystalline form of eniconazole begins to decompose at 150 ℃ and is completely decomposed at 210 ℃; preferably with a thermogravimetric analysis curve as shown in figure 3.
In another embodiment of the present invention, a method for preparing the crystalline form of enilconazole described above is provided, wherein a crude enilconazole is added to a solvent, heated and stirred for the first time, and filtered; and (3) heating and stirring the filtered product for the second time, cooling after dissolving, stirring and crystallizing, filtering, and drying under reduced pressure to obtain the product.
Based on the knowledge of those skilled in the art, the solvents used for crystallization in the prior art are various, and the mixed solvents composed of solvents with different types and proportions cannot be counted, and the design of crystallization is based on experience, so that the obtained crystal form cannot be predicted according to crystallization conditions.
In one embodiment, in the preparation method of the enilconazole crystal form, the solvent is one of dichloromethane, butyl acetate, methyl tert-butyl ether, n-hexane, ethyl acetate or toluene. In a preferred embodiment, the volume ratio of the crude enilconazole to the solvent is 1: (0.5-10). And the solvent lost due to the first filtration is supplemented during the secondary heating and stirring, so that the impurity precipitation capacity is ensured. In the process, the stirring time, the heating temperature and the heating time are determined by fully dissolving the crude product in the solvent and fully separating out impurities, the crystallization process is carried out in a cooling process, the crystallization time influences the yield of the crystal form, and the preferable time is 2-8h. The yield of the prepared enoconazole crystal form can reach more than 90%, the purity reaches more than 99.9%, and the single impurity is less than 0.1%.
In one embodiment, a bactericidal or bacteriostatic drug is provided, which comprises the crystal of the above embodiment and a pharmaceutically acceptable excipient, preferably consists of the crystalline form of enilconazole of the above embodiment and a pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients include, but are not limited to, common fillers, stabilizers, diluents, adjuvants or other formulation excipients, based on routine selection in the art.
In one embodiment, a method for detecting the crystalline form of enilconazole is provided, wherein an X-ray powder diffraction detection is performed on a suspected crystal, and the obtained X-ray powder diffraction pattern is compared with an X-ray powder diffraction pattern shown in figure 1. Those skilled in the art can obtain the diffraction pattern of the crystal using X-ray powder diffraction detection equipment, which is commercially available. The detection conditions may also be well known to those skilled in the art, such as voltage: current, cu-ka radiation, etc. According to parameters such as line position, line height, relative abundance and/or interplanar distance d (usually expressed) of the spectrum, a person skilled in the art can compare whether the suspected crystal is the enilconazole crystal form provided by the invention.
The following examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
XRPD: x-ray powder diffraction (also known as XRPD);
DSC: differential Scanning Calorimetry, differential Scanning Calorimetry;
TGA: thermal gravimetric analysis, thermogravimetric analysis;
XRPD testing used an EMPYREAN X-ray diffractometer from PANalytical b.v. netherlands. Appropriate amount of samples were spread evenly on the single crystal silicon sample plate and the test parameters are shown in table 1.
Table 1: XRPD test conditions
DSC and TGA spectra were collected on a Diamond DSC differential scanning calorimeter of PerkinElmer, USA, and a Pyris1TGA thermogravimetric analyzer of PerkinElmer, USA, and the test parameters are shown in Table 2.
Table 2: DSC and TGA test parameters
DSC | TGA | |
Sample plate | Hollow AI crucible (tablet) | Air AI crucible (tablet) |
Temperature range (. Degree.C.) | 30-60 | 30-500 |
Rate of temperature rise (. Degree. C./min) | 5 | 5 |
Protective gas | High purity N 2 | High purity N 2 |
Crude enilconazole as used herein refers to the compound as an oil, without crystallization. In the application, because the eniconazole cannot be completely dissolved in the solvent, heating and stirring are required to remove impurities contained in the eniconazole crude product, so that the eniconazole is crystallized again, and the eniconazole crystal form provided by the application is prepared through subsequent steps.
In the present application, the purity of the crystalline form refers to the content of the crystalline form after removing crystalline or amorphous enoconazole and other impurities, and the determination method is determined by GC.
It will be appreciated that slightly different melting point readings may be given with different types of equipment or with different test conditions. The exact values of the melting points of the different crystal forms will be influenced by the purity of the compound, the weight of the sample, the heating rate, the particle size and the calibration and maintenance of the test equipment. The values provided cannot be taken as absolute values.
It should be understood that slightly different XRPD patterns and peaks may be given with different types of equipment or with different test conditions. The spectra, peak values and relative intensities of the various diffraction peaks of the different crystal forms will be affected by the purity of the compound, the pre-treatment of the sample, the scanning speed, the particle size and the calibration and maintenance of the test equipment. The numerical values provided cannot be taken as absolute values.
Example 1
Adding 20g of the oily crude product of enilconazole into 10mL of ethyl acetate, stirring and heating to 38 ℃, preserving heat and stirring for 1.0h, performing heat filtration, supplementing ethyl acetate lost by suction filtration to 10mL, heating and stirring to 36 ℃, preserving heat and stirring for 1.0h, cooling to 5 ℃, preserving heat and stirring for 4h, performing crystallization, filtering, and drying at 30 ℃ under reduced pressure for 24h to obtain 18g of refined product, wherein the yield is as follows: 90%, purity (GC assay): 99.95 percent and less than 0.1 percent of single impurity. The obtained refined product was subjected to XRPD, and the obtained XRPD pattern is shown in FIG. 1, and the peak information thereof is shown in Table 3. A typical DSC diagram is shown in fig. 2, with a melting point of 53 ℃ and a melting range of 52..0-54.0 ℃ as interpreted from fig. 2. A typical TGA profile is shown in figure 3. The resulting enilconazole crystals were free of water or other solvents as evidenced by the H-NMR plot of fig. 4. The obtained refined product is the enilconazole crystal form.
Table 3: powder diffraction data of samples obtained in example 1
Example 2
Adding 100g of oily enoconazole crude product into 200mL of dichloromethane, stirring and heating to 32 ℃, preserving heat and stirring for 0.5h, performing heat filtration, supplementing dichloromethane lost by suction filtration to 200mL, heating and stirring to 30 ℃, preserving heat and stirring for 0.5h, cooling to 8 ℃, preserving heat and stirring for 8h, crystallizing, filtering, and drying at 30 ℃ under reduced pressure for 12h to obtain 85g of refined product, yield: 85%, purity (GC assay): 99.92 percent and less than 0.1 percent of single impurity. The obtained refined product was subjected to XRPD, XPRD as shown in FIG. 5 (EKZ-1), and information on the peak value of the diffraction pattern as shown in Table 4, which was substantially in accordance with the results of FIG. 1. The obtained refined product is the enilconazole crystal form.
Table 4: example 2 powder diffraction data of samples
Example 3
Adding 500g of oily enoconazole crude product into 1500mL of butyl acetate, stirring and heating to 38 ℃, preserving heat and stirring for 1.0h, carrying out heat filtration, supplementing butyl acetate lost by suction filtration to 1500mL, heating and stirring to 40 ℃, preserving heat and stirring for 0.5h, cooling to 0 ℃, preserving heat and stirring for 5h, crystallizing, filtering, and drying at 30 ℃ under reduced pressure for 30h to obtain 1380g of refined product, yield: 92%, purity (GC assay): 99.91 percent and less than 0.1 percent of single impurity. The refined product thus obtained was subjected to XRPD (EKZ-2, FIG. 5), and the peak information of XPRD pattern was substantially in accordance with the results shown in FIG. 1, as shown in Table 5. The obtained refined product is the enilconazole crystal form.
Table 5: powder diffraction data of sample obtained in example 3
Example 4
Adding 200g of oily crude enilconazole into 2000mL of methyl tert-butyl ether, stirring and heating to 52 ℃, preserving heat and stirring for 1.0h, performing heat filtration, supplementing the lost methyl tert-butyl ether to 2000mL, heating and stirring to 55 ℃, preserving heat and stirring for 1.0h, cooling to 22 ℃, preserving heat and stirring for 5h, performing crystallization, filtering, and drying under reduced pressure at 30 ℃ for 10h to obtain 188g of refined product, wherein the yield is as follows: 94%, purity (GC assay): 99.93 percent and less than 0.1 percent of single impurity. The obtained refined product was subjected to XRPD (EKZ-3, FIG. 5), and the information on the peak value of the diffraction pattern is shown in Table 6, and substantially agrees with the result of FIG. 1. The obtained refined product is the enilconazole crystal form of the application.
Table 6: powder diffraction data of sample obtained in example 4
Example 5
Adding 30g of the oily crude product of enilconazole into 600mL of n-hexane, stirring and heating to 67 ℃, keeping the temperature and stirring for 1.0h, performing heat filtration, supplementing the n-hexane lost by suction filtration to 600mL, heating and stirring to 69 ℃, keeping the temperature and stirring for 1.0h, cooling to 30 ℃, keeping the temperature and stirring for 2h for crystallization, filtering, and drying at 30 ℃ under reduced pressure for 10h to obtain 28.5g of refined product, wherein the yield is as follows: 95%, purity (GC assay): 99.90 percent and less than 0.1 percent of single impurity. The resulting refined product was subjected to XRPD (EKZ-4, FIG. 5), and the information on the peak value of the diffraction pattern is shown in Table 7, which is substantially in accordance with the results shown in FIG. 1. The obtained refined product is the enilconazole crystal form.
Table 7: powder diffraction data sheet of sample obtained in example 5
Example 6
Adding 1000g of oily enoconazole crude product into 2000mL of toluene, stirring and heating to 55 ℃, preserving heat and stirring for 0.5h, performing heat filtration, supplementing toluene lost by suction filtration to 2000mL, heating and stirring to 60 ℃, preserving heat and stirring for 0.5h, cooling to 30 ℃, preserving heat and stirring for 5h, performing crystallization, filtering, and drying at 30 ℃ under reduced pressure for 36h to obtain 890g of refined product, wherein the yield is as follows: 89%, purity (GC assay): 99.95 percent and less than 0.1 percent of single impurity. The obtained refined product was subjected to XRPD (EKZ-6, FIG. 5), and the information on the peak value of the diffraction pattern is shown in Table 8, and substantially agrees with the result of FIG. 1. The obtained refined product is the enilconazole crystal form of the application.
Table 8: example 6 powder diffraction data sheet of the sample
In the above examples 1 to 6, the crystalline forms of eniconazole prepared by different solvents were numbered as shown in table 9, and XRPD diffraction pattern peak information and DSC curve characteristics of the crystalline forms were compared as shown in fig. 5 and 6, respectively. The high consistency of the diffraction pattern peak value information can be easily seen; in a DSC curve, the first endothermic peak appears in the enilconazole crystal form at 50-53 ℃, the peak value of the first endothermic peak appears at 53-55 ℃, and the enilconazole crystal form has consistency.
Table 9: sample information
Crystallization solvent | Sample numbering | Corresponding embodiment |
Methylene dichloride | EKZ-1 | Example 2 |
Acetic acid butyl ester | EKZ-2 | Example 3 |
Methyl tert-butyl ether | EKZ-3 | Example 4 |
N-hexane | EKZ-4 | Example 5 |
Ethyl acetate | EKZ-5 | Example 1 |
Toluene | EKZ-6 | Example 6 |
Stability test of Crystal form
Stability tests were performed on the crystalline forms of eniconazole prepared in examples 1 to 6, and the relevant indexes were measured by leaving for different times, and the test results are shown in table 10.
Table 10: results of stability test
Compared with the initial (0 month), the stability test result of the Enconazole crystal form of the application shows that the indexes of the key investigation items of the Enconazole crystal form are not obviously changed compared with the initial test time (0 month), the purity is more than 99.0%, the single impurity content is less than 0.1%, and the stability is relatively stable.
In table 9:
"Total hetero" means: the total amount and the mass percentage of impurities contained in the enilconazole crystal form;
"moisture" means: the amount and the mass percentage of the water contained in the eniconazole crystal form;
"content" means: the content (taking a standard as a reference) and the mass fraction of the effective components of the enilconazole in the enilconazole crystal form;
melting point determination method: adding the eniconazole prepared by the method into a capillary tube to form a compact column with the height of about 3mm, and testing the melting point according to the four-part general rule 0612 of the 2020 edition of Chinese pharmacopoeia;
the water content measuring method comprises the following steps: taking a proper amount of eniconazole prepared by the application, and measuring according to a moisture determination method (0823 first method 1 of the four ministry of general rules of China pharmacopoeia 2020); the single impurity and total impurity content determination method comprises the following steps: measured according to gas chromatography (China pharmacopoeia 2020 edition four-part general rules 0512).
Finally, although the present invention has been described in detail by way of general description and specific examples, the above examples are only intended to illustrate the technical solutions of the present invention, but not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. An enilconazole crystalline form characterized by characteristic peaks in an X-ray powder diffraction pattern expressed as Cu-K α radiation at 2 θ ± 0.2 ° diffraction angles at 9.3045, 13.3046, 14.8313, 20.2166, 20.6254, 20.7572, 21.0752, 22.7064, 22.9297, 23.4409, 23.6543, 24.4229, 25.2438, 27.7342, 28.4334, 28.5207.
2. The crystalline form of eniconazole according to claim 1, characterized by the X-ray powder diffraction pattern as shown in figure 1.
3. The crystalline form of eniconazole according to claim 1, wherein a differential scanning calorimetry curve shows a first endothermic peak at 50-53 ℃ and the peak of the first endothermic peak at 53-55 ℃.
4. The crystalline form of eniconazole according to claim 1, wherein the thermogravimetric analysis curve begins to decompose at 150 ℃ and is completely decomposed at 210 ℃.
5. A method for preparing the crystalline form of enilconazole as defined in any one of claims 1 to 4, wherein a crude enilconazole is added to a solvent, stirred under heating for a first time and filtered; and (3) heating and stirring the filtered product for the second time, cooling after dissolving, stirring and crystallizing, filtering, and drying under reduced pressure to obtain the product.
6. The method of claim 5, wherein the solvent is one of dichloromethane, butyl acetate, methyl tert-butyl ether, n-hexane, ethyl acetate, or toluene.
7. The preparation method of claim 5, wherein the volume ratio of the crude enilconazole to the solvent is 1: (0.5-10).
8. The method according to claim 5, wherein the time of the crystallization process is 2 to 8 hours.
9. Use of the crystalline form of enilconazole of any one of claims 1 to 4 in the preparation of a bactericidal or bacteriostatic medicament.
10. A method for detecting the crystalline form of enilconazole as defined in claim 1 or 2, wherein the suspected crystals are subjected to an X-ray powder diffraction detection and the X-ray powder diffraction pattern obtained is compared with an X-ray powder diffraction pattern shown in fig. 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211286225.9A CN115433132A (en) | 2022-10-20 | 2022-10-20 | Enconazole crystal form, preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211286225.9A CN115433132A (en) | 2022-10-20 | 2022-10-20 | Enconazole crystal form, preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115433132A true CN115433132A (en) | 2022-12-06 |
Family
ID=84252525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211286225.9A Pending CN115433132A (en) | 2022-10-20 | 2022-10-20 | Enconazole crystal form, preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115433132A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116082245A (en) * | 2022-12-26 | 2023-05-09 | 武汉工程大学 | Enconazole crystal and preparation method and application thereof |
-
2022
- 2022-10-20 CN CN202211286225.9A patent/CN115433132A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116082245A (en) * | 2022-12-26 | 2023-05-09 | 武汉工程大学 | Enconazole crystal and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080182856A1 (en) | Novel crystalline forms of aripiprazole | |
CN115433132A (en) | Enconazole crystal form, preparation method and application | |
US20090247542A1 (en) | Syntheses and preparations of polymorphs of crystalline aripiprazole | |
CN106220624B (en) | The method for preparing Eliquis N-1 forms | |
AU2022325334A1 (en) | Crystal form of lanifibranor, preparation method therefor, and use thereof | |
CN109776416B (en) | Bulleyaconitine A C crystal form and preparation method and application thereof | |
CN109734664B (en) | Bulleyaconitine A D crystal form and preparation method and application thereof | |
CN106866666B (en) | Palbociclib crystal form compound and preparation method thereof | |
US20220153704A1 (en) | Crystal form e of bulleyaconitine a, preparation method therefor and application thereof | |
CN113966332A (en) | Polymorphic substance of CDK9 inhibitor and preparation method and application thereof | |
CN113896649B (en) | Prilocaine crystal form and preparation method thereof | |
CN105777651A (en) | Crystal form of poly adenosinediphosphate-ribose polymerase (PARP) inhibitor, preparation method for crystal form and medicinal use of crystal form | |
WO2011100282A2 (en) | Imatinib mesylate polymorphs | |
CN116041351A (en) | Novel midazolam hydrochloride crystal form and preparation method thereof | |
CN111320601B (en) | Oroxylin crystal form and preparation method thereof | |
CN109776543A (en) | Buddhist nun's salt, its crystal, preparation method, pharmaceutical composition and application are replaced according to Shandong | |
CN110776450B (en) | Siponimod crystal form and preparation method thereof | |
CN114644681B (en) | Nemactet Wei Yi propanol solvate crystal form and preparation method thereof | |
EP2767544A1 (en) | Amorphous substance of 17 -acetoxy-11 -(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and preparation method thereof | |
WO2014092589A1 (en) | Process for preparation of prasugrel hydrochloride polymorphic form b of pharmaceutical purity | |
US20040186112A1 (en) | Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof | |
CN115768753B (en) | Crystal form of GABA inhibitor and preparation method thereof | |
CN116041275B (en) | Crystal form A of ritodrine, preparation method and application thereof | |
CN113603673B (en) | Crystal form of duloxetine hydrochloride, preparation method and application thereof | |
EP0189679B1 (en) | Novel crystalline form of 1-benzhydryl-4-allylpiperazine dihydrochloride and method for the production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240717 Address after: 432000 South of Heng'er Road and West of Zong'er Road, Yingcheng Economic Development Zone, Xiaogan City, Hubei Province Applicant after: Hubei Hesheng Biopharmaceutical Co.,Ltd. Country or region after: China Address before: 430040 No. 218, Zhangbai Road, Dongxihu District, Wuhan City, Hubei Province Applicant before: WUHAN HVSEN BIOTECHNOLOGY CO.,LTD. Country or region before: China |